Acromicric dysplasia due to a novel missense mutation in the fibrillin 1 gene in a three-generation family

J Pediatr Endocrinol Metab. 2022 Aug 9;35(11):1443-1447. doi: 10.1515/jpem-2022-0287. Print 2022 Nov 25.

Abstract

Objectives: Short stature is one of the most common reasons for consulting a paediatric endocrinologist. Targeted diagnosis of familial short stature can be challenging due to a broad spectrum of differential diagnoses.

Case presentation: Here we report a novel mutation in the fibrillin 1 gene (FBN1) in six family members causing a mild phenotype of acromicric dysplasia. Additionally, we present the effects of growth hormone therapy in one of the affected children.

Conclusions: Acromicric dysplasia is a very rare skeletal dysplasia with a prevalence of <1 of 1.000.000 with only about 60 cases being reported worldwide. It is characterized by short stature, acromelia, mild facial dysmorphy but normal intelligence. This study aims to exemplify the clinical and molecular features of FBN1-related acromicric dysplasia and illustrates its pleiotropy by presenting a new, mild phenotype.

Keywords: FBN1; acromicric dysplasia; short stature.

Publication types

  • Case Reports

MeSH terms

  • Bone Diseases, Developmental* / genetics
  • Dwarfism*
  • Fibrillin-1 / genetics
  • Humans
  • Limb Deformities, Congenital* / genetics
  • Mutation
  • Mutation, Missense

Substances

  • Fibrillin-1

Supplementary concepts

  • Acromicric dysplasia